Open AccessACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What's the Evidence?
Author(s) -
Bakris George L.,
Weir Matthew
Publication year - 2002
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2002.01641.x
Subject(s) - medicine , diabetic nephropathy , type 2 diabetes , diabetes mellitus , nephropathy , kidney disease , angiotensin converting enzyme , population , ace inhibitor , disease , blood pressure , endocrinology , environmental health
Although angiotensin‐converting enzyme inhibitors are frequently used as antihypertensive agents to lower blood pressure and slow progression of nephropathy in patients with type 2 diabetes, evidence of their efficacy has been drawn primarily from small trials with surrogate end points. No adequately powered, long‐term trials have tested their effects to reduce the incidence of hard end points, such as progression to end‐stage renal disease or even doubling of serum creatinine in the population of patients with nephropathy from type 2 diabetes. While the results of angiotensin‐converting enzyme inhibitor trials from nondiabetic causes and even type 1 diabetes may be extrapolated to the patient with nephropathy associated with type 2 diabetes, the hard evidence is not available. This review critically evaluates the limited evidence in support of angiotensin‐converting enzyme inhibitors as renal‐protective agents in people with type 2 diabetes.